Lung Cancer prognosis

Reading time: 2 min

Lung cancer, along with pancreatic and oesophageal cancer, is one of the most aggressive tumours. It is estimated that 15% of patients with lung cancer survive more than five years. This is because of the aggressive nature of the tumour and small chance of an early diagnosis.

The lung cancer overall survival rate has improved considerably in recent years with the introduction of new treatments and imaging techniques. Nevertheless, lung cancer is still the first cause of cancer-related death across the world.

It is important to remember that these statistics are only population estimates and each individual case often follows its own course.

Two doctors separated by a line representing the act of requesting a second opinion

Request a second opinion in another hospital if you have any doubts about your treatment. Patients should always follow treatment in the centre and with the healthcare team they trust the most.

Patient talking to healthcare staff

Discuss things with your healthcare professionals. Must be many questions as you need to in order to resolve your doubts about the disease and its treatment. It is a good idea to write them in a notebook so that you don't forget them. Whenever possible, have someone accompany you to your appointments to help you understand the information.

Crossed fingers

Keep your hopes up. There are aspects about each case of lung cancer that even the experts cannot foresee, such as how patients will respond to treatment and how the disease will evolve. Therefore, you should learn as much information as possible about your treatment progress and test results during each appointment.

What is Cancer?

General information about Cancer

Read more

Substantiated information by:

David Sánchez Lorente
Laureano Molins López-Rodó
Mari Carmen Rodríguez Mues
Noemí Reguart Aransay
Nuria Viñolas Segarra
Ramón Marrades Sicart

Published: 20 February 2018
Updated: 20 February 2018

The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.


Receive the latest updates related to this content.

Thank you for subscribing!

If this is the first time you subscribe you will receive a confirmation email, check your inbox

An error occurred and we were unable to send your data, please try again later.